Agenus Inc. (NASDAQ:AGEN) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET

Company Participants

Nico Frelick - Investor Relations

Dr. Garo Armen - Chairman and Chief Executive Officer

Christine Klaskin - Vice President of Finance

Dr. Steven O'Day - Chief Medical Officer

Dhan Chand - Scientific Director, Head of Drug Discovery

Conference Call Participants

David Dye - SNBC

Matt Phipps - William Blair

Mayank Mamtani - B. Riley Securities

Kelly Shi - Jefferies

Operator

Thanks for holding, and welcome everyone to the Agenus Third Quarter 2022 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

I'll now turn the call over to Nico Frelick from Investor Relations. Mr. Freelik, please go ahead.

Nico Frelick

Thank you, Jack, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that, this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and timelines as well as timelines for data release and partnership opportunities. These statements are subject to risks and uncertainties and we refer you to our SEC filings for more details on these risks.

Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; and Christine Klaskin, Vice President of Finance. Our Chief Medical Officer, Dr. Steven O'Day, will be joining us for Q&A.

Now, I'd like to turn the call over to Garo to highlight our progress and speak to our outlook for remainder of the year. Garo?

Dr. Garo Armen

Thank you, Nico. Once again, good morning and thank you for joining [Technical difficulty] yesterday for our third quarter update and numbers discussion. It is an exciting time for Agenus and we believe also for the field of immuno-oncology.

The Society for Immunotherapy of Cancer otherwise known as SITC Conference starts today in Boston, our home turf, during which we expect to highlight the significant unrealized potential for a new generation of I-O regimens, I-O being immuno-oncology, that potentially would transform the way we treat cancer.

We anticipate that one of our most promising clinical assets balstilimab, a novel adaptive innate immune activator in addition to being a CTLA-4 binder can provide important future therapeutic options for patients with tumors that are particularly resistant to current therapies, including very importantly immunotherapies.